Recent blog posts
Global Pharmaceutical Industry Financing Transactions Weekly Report (10.28-11.3)
DrugDeal Decode
10 min read
Global Pharmaceutical Industry Financing Transactions Weekly Report (10.28-11.3)
5 November 2024
10.28-11.3, Global Pharmaceutical Investment, Financing and Deal Events Summary.
Read →
Global Pharmaceutical Industry Financing Transactions Weekly Report (9.16-9.22)
DrugDeal Decode
9 min read
Global Pharmaceutical Industry Financing Transactions Weekly Report (9.16-9.22)
23 September 2024
Summary of Global Pharmaceutical Licensing Agreements and Financing Events from September 16 to September 22.
Read →
Global Pharmaceutical Industry Financing Transactions Weekly Report (9.9-9.15)
DrugDeal Decode
10 min read
Global Pharmaceutical Industry Financing Transactions Weekly Report (9.9-9.15)
19 September 2024
This week, multinational pharmaceutical companies including Sanofi, Bayer, Gilead Sciences, Novo Nordisk, and Pfizer have been notably active.
Read →
How to quickly read pharmaceutical company financial reports?
DrugDeal Decode
6 min read
How to quickly read pharmaceutical company financial reports?
28 August 2024
This article will use Pfizer as an example to teach you how to quickly learn to read Pharma/Biotech financial reports.
Read →
Bristol Myers Squibb Invests in Cancer Immunotherapy Targeting GPR65
DrugDeal Decode
4 min read
Bristol Myers Squibb Invests in Cancer Immunotherapy Targeting GPR65
19 April 2024
Pathios Therapeutics Secures $25M in Series B Funding for Cancer Drug Development.
Read →
Exploring the Latest Long Acting Injection Deal by Medincell: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest Long Acting Injection Deal by Medincell: A Guide to Rapidly Accessing Transaction Insights
18 April 2024
Medincell and AbbVie Partner to Co-Develop Six Long-Acting Injectables.
Read →
Exploring the Latest BAFF/APRIL antagonist therapy Deal by Alpine Immune Sciences: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest BAFF/APRIL antagonist therapy Deal by Alpine Immune Sciences: A Guide to Rapidly Accessing Transaction Insights
18 April 2024
On April 10, 2024, Vertex Pharmaceuticals ("Vertex") and Alpine Immune Sciences ("Alpine") announced that the parties entered into a definitive agreement. the parties have entered into a definitive agreement.
Read →
Exploring the Latest AR PROTAC Deal by Arvinas: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest AR PROTAC Deal by Arvinas: A Guide to Rapidly Accessing Transaction Insights
18 April 2024
On April 12, 2024, Arvinas announced that it has entered into an exclusive strategic license agreement with Novartis to collaborate on the development of Arvinas' second-generation androgen receptor (AR) degrader, ARV-766.
Read →
Viatris: Layout of Potential Products for Acute Myocardial Infarction and Systemic Lupus Erythematosus
DrugDeal Decode
10 min read
Viatris: Layout of Potential Products for Acute Myocardial Infarction and Systemic Lupus Erythematosus
19 March 2024
On February 28th, US-based Viatris and Swiss firm Idorsia launched a major R&D partnership, with Viatris securing exclusive global rights for two Phase 3 drugs, Selatogrel and Cenerimod, and options for future joint projects.
Read →
Atai Strategic Investment in Beckley Psytech to Jointly Develop Rapid-Acting Psychedelic Medications for the Treatment of Depression
DrugDeal Decode
5 min read
Atai Strategic Investment in Beckley Psytech to Jointly Develop Rapid-Acting Psychedelic Medications for the Treatment of Depression
15 March 2024
clinical-stage biopharma atai Life Sciences (NASDAQ: ATAI), focused on transforming mental health treatment, announced a strategic investment in Beckley Psytech, cementing its position as the bio-pharma leader with the broadest portfolio of clinical-stage psychedelic drug candidates.
Read →
Exploring the Latest PD-1 inhibitor Deal by ImmVirX: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest PD-1 inhibitor Deal by ImmVirX: A Guide to Rapidly Accessing Transaction Insights
29 February 2024
On February 21, 2024, Innovent Biologics and ImmVirX unveiled a partnership for clinical research on a combo therapy using sintilimab and the cancer-fighting virus IVX037.
Read →
Exploring the Latest OX40 inhibitors Deal by Hutchmed: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest OX40 inhibitors Deal by Hutchmed: A Guide to Rapidly Accessing Transaction Insights
29 February 2024
Hutchmed and Inmagene have exercised licensing options for two drug candidates, IMG-007 and IMG-004, as per their strategic collaboration agreement.
Read →